PRINCETON, N.J. & PARIS--(BUSINESS WIRE)--STENTYS (Paris:STNT) (FR0010949404 — STNT), a medical technology company commercializing, in Europe, the world's first and only Self-Apposing® stent to treat acute myocardial infarction (AMI), today announces revenues for the third-quarter and nine-months ended September 30, 2014.
- Change in third-quarter and nine-month revenues*
| 9 months | Quarterly – 3 months | |||||||||||||
| € thousand | 9 months 2014 | 9 months 2013 | % change | Q3 2014 | Q3 2013 | % change | ||||||||
| Revenues | 2,812.4 | 2,406.6 | +16.9% | 876.5 | 768.0 | +14.1% | ||||||||
* Data reviewed by the statutory auditors
STENTYS recorded revenues of €876.5 thousand over the third quarter of 2014, up 14.1% compared with the third quarter of 2013. This growth was driven by sales of its current range of self-apposing stents both directly via the Company and through its network of distribution partners in various regions around the world.
For the first nine months of the year, revenues totaled €2.8 million, up 16.9% compared with the same period of 2013.
- A sound cash position
At September 30, 2014, STENTYS had cash and equivalents totaling €20 million compared with €23.1 million at June 30, 2014.
Gonzague Issenmann, Chief Executive Officer and co-founder of STENTYS, explains: “The quarterly sales growth is progressing smoothly with our current product portfolio, as illustrated by the latest success with the regional tender in the Middle East for 2015. We intend to pursue our sales coverage strategy in high-potential geographies by creating strong partnerships with the best local distributors.”
About STENTYS
STENTYS is developing and commercializing
innovative solutions for the treatment of patients with acute myocardial
infarction (AMI, or heart attack) and complex coronary artery disease.
STENTYS’s Self-Apposing® Stents are designed to adapt to vessels with
ambiguous or fluctuating diameters, particularly in the post-infarction
phase, in order to prevent the malapposition problems associated with
conventional stents. In the APPOSITION III clinical trial, STENTYS
stents demonstrated a very low one year mortality rate among 1,000
high-risk AMI patients when compared to recent studies with conventional
stents. More information is available at www.stentys.com.
STENTYS is listed on Comp. B of Euronext Paris
ISIN: FR0010949404 –
Ticker: STNT
